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EDITORIAL REVIEW
T cell regulation, anti-idiotypic immunity, and the
nephritogenic immune response
It is generally agreed that most forms of nephritis probably
have an immunologic basis. This belief is supported by a large
number of studies focusing on the nephritogenic immune re-
sponse as it occurs locally within the kidney. One outgrowth of
these immunologic investigations is the now classical subdivi-
sion of renal histopathology into the effector pathways of
antibody [1—3], immune deposit [4—7], and cell-mediated dis-
ease [8—9]. The thorough study of these effector pathways has
greatly enhanced our understanding of the inflammatory mech-
anisms directly involved in developing immunopathology [8,
10]. There is, however, another aspect to immune-mediated
renal disease which is the rapidly growing area of immune
regulation. Interest in this subject has emerged as one of several
fascinating developments within the field of basic immunology
and has been sustained because a variety of experimental
observations now suggests that immune regulation has an
important role in defining the natural history of an immune
response. In the context of renal disease, immune regulation
can be viewed as a complex network of antibody and cell-
mediated circuits usually operating to produce feedback sup-
pression and down-regulation leading to the eventual control of
on-going renal injury. The interdigitation of such regulatory
systems with the more traditional areas of renal immunology
has not been formally defined. As this integration occurs,
however, the subject of immune regulation will more than likely
find a permanent and, perhaps, prominent place within the
broader view of the nephritogenic immune response.
It is interesting to observe from a historical perspective that
the complexity of the immunoregulatory process during renal
injury was not initially appreciated. Prior to its present status
immune regulation was viewed in much simpler terms. The
modern study of immune-mediated renal disease, for example,
was primarily influenced many years ago by Burnet's theory of
clonal selection [11]. Simply stated this theory predicted that a
new antigen bound to pre-existing lymphoid cells would cause
them to proliferate and secrete antibodies. In competition for
antigen only those cells with high affinity receptors for the
antigen continued to proliferate. Free high affinity antibody
united with antigen either in the body fluid or within parenchy-
mal tissues preventing the further stimulation of antigen-reac-
tive clones. In this way antibody removed antigen, thus acting
as a negative feedback system, and the lymphocyte clones with
high affinity receptors remained as a memory for long-lasting
immunity. It is perhaps a measure of the great influence of
Burnet's theory that nephrologists traditionally have viewed
most aspects of the nephritogenic immune response only in
terms of antigen-antibody interactions. The existence of more
complicated regulatory processes, including the role of the cell-
mediated immune response, have all slowly evolved out of a
background set in the clonal selection theory. It is only now
becoming clear that the humoral and cell-mediated immune
responses are closely interrelated at many functional levels.
There is no better example of this interplay than in the area of
immune regulation. Out of this integrative complexity it would
also not be surprising to find that regulatory networks may
provide new and additional pathogenic pathways for immune-
mediated renal disease (Fig. 1). That is, defects or alterations in
regulatory systems may create a permissive environment for
the uncontrolled expression of effector responses producing
renal injury [12—241. Furthermore, correcting such alterations in
immune regulation may provide another direction for therapeu-
tic interventions intending to reduce host morbidity. It is the
purpose of this review to relate recent observations in the area
of immune regulation to the development of nephritis. Within
this framework we will focus on the concepts of T cell function
and the role of anti-idiotypic immunity in the control of the
nephritogenic immune response.
Immunologic circuits and the network theory of immune
regulation
A normal individual does not destroy his own parenchymal
tissues because immune mechanisms capable of producing such
injury are specifically inhibited by regulatory systems acquired
during ontogeny [25, 26]. The early evolution of tolerance to
these self-determinants has an important selective advantage
for the organism [27, 28]. Regulatory systems during life are
also activated following the exposure of the immune system to
new antigens. Their effectiveness measurably influences,
among other things, the overall level of activity of the mediators
that may produce chronic inflammation. The actual mechanism
regulating the immune response to complex antigens is deter-
mined to a large extent by the T cell repertoire. T cells can be
divided into subpopulations or sets of lymphocytes displaying
different functions. Such subpopulations can be distinguished
by cell-surface markers encoded by genes activated during
thymic differentiation [12, 29—32]. Helper/inducerT cells (Ly l
in the mouse; OKT4 in the human) can induce B cells to make
antibodies, other mononuclear cells to participate in delayed
hypersensitivity reactions, and killer cell precursors to become
cytotoxic effector cells. Suppressor T cells (Ly 2,3k in the
mouse; OKT5/8 in the human) can inhibit both humoral and
cell-mediated immune responses. A third type of T lymphocyte
(Ly 1,2,3k in the mouse; OKT 4, 5, 8 in the human) appears
to be an intermediate/amplifier cell that can differentiate into
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Fig. 1. Presentation of a new antigen to the immune system. The ability
to make an immune response principally depends on whether or not the
host has the appropriate immune response genes. When these immune
response genes are present, antibodies, immune complexes, and/or a
cell-mediated immune response may ensue. These mediators of immu-
nopathology are balanced by a concomitant regulatory response which
provides the control necessary to avoid major target organ damage
during the countless self-limited immune reactions generated by the
host within its environment. The regulatory mechanism comprises a
complex network of T cells and antibodies coordinated as an anti-
idiotypic immune response. These regulatory responses will be illustrat-
ed more fully in subsequent figures.
more mature helper or suppressor cells. The helper T cell is the
pivotal cell required for activating and expanding the immune
response. Once this process is begun all three groups of cells
subsequently function as a dynamic modulating unit which
normally feeds back to down-regulate or suppress the antigen-
induced immune response (Fig. 2). As an example, a helper T
cell activated by a conventional antigen stimulates the develop-
ment of a variety of effector cells for the purpose of carrying out
the immune response. A subset of these helper cells, however,
also induces a suppressor cell from the intermediate pool of
cells [12, 33]. This new suppressor cell eventually inhibits the
immunologic activity stimulated by the original helper cell.
Within this complicated interplay, such T cell interactions can
also influence which of the responding lymphocyte clones best
recognizes the antigen [34] as well as control the intensity and
duration of an enlarging immune response [35, 36]. While some
of these immunologic circuits may operate through cell to cell
contact, there is growing evidence that much of network
communication is accomplished by soluble lymphokines re-
leased by activated cells. There are two general groups of these
lymphokines; those which are antigen-specific and those which
are not. Of the latter group the interleukins have received much
attention. Interleukin 1 is an accessory cell-derived peptide
which prepares a T cell to respond to its antigen [37]. It also
induces the secretion of helper T cell-derived interleukin 2, a
soluble lymphokine which can amplify an antigen-reactive
immune response by recruiting other helper T cells [38]. These
nonspecific lymphokines are essential for successful T cell
activation. Specific communication between antigen-reactive
lymphocytes, however, is largely accomplished by signals
derived from soluble antigen-specific helper and suppressor
factors. These specific factors are released by appropriately
activated cells and, in many cases, function only according to
genetically defined rules [39, 40].
Which individuals of a species make a T cell response to a
particular antigen is determined, in part, by the immune re-
sponse genes carried in their major histocompatibility complex
(MHC) [41—43] (See Appendix of this review for complete
glossary.). Such genes also play an important role in determin-
ing the susceptibility to autoimmune disease [44]. Immune
response genes exert their influence by providing gene products
for modulating or influencing two basic lymphocyte functions:
those of intensity and those related to restriction. Intensity of
an immune response is relatively easy to conceptualize while
restriction is slightly more difficult. The intensity of an immune
response is genetically determined not only by the presence of
antigen-reactive lymphocytes, but also by the relative balance
between helper and suppressive influences [45]. Restriction
refers to the fact that T lymphocytes recognize relevant anti-
gens only when they are presented to the T cell in the context of
certain gene products and not in the presence of others. So, for
example, if a T helper cell is going to respond to its antigen, this
antigen must be processed by an accessory cell and seen in
association with certain class II MHC antigens (I region in the
mouse; HLA-DIDR region in the human) which are also ex-
pressed on the surface of these antigen-presenting cells [46—49].
In a similar fashion, for cytotoxic T cells to lyse their target
they, too, must see their antigenic determinant in relation to
selected class I MHC antigens (KID regions in the mouse;
HLA-A,B,C regions in the human) found on the target cell
surface [47, 50, 51]. These restriction requirements, as a group,
provide important activation or control signals for potential T
cell immune responses to complex antigens.
When helper T cells are activated following antigen-recogni-
tion, a number of responding clones are initially involved. Their
receptors for the antigen have varying degrees of affinity for
that antigen and this variability is distributed among the re-
sponding clones. If each of the responding helper T cells
induces a variety of suppressor T cells, effector T cells, and B
cells that all see only one molecular region of an antigen, and, if
the antigen has many molecular determinants which will acti-
vate different groups of T and B cells, one has to wonder how
the individual responding members of the immune system can
all communicate with one another and, in a larger sense, how
the immune system can regulate this breadth of activity. There
is a growing belief that a large part of this coordination is
probably the direct result of the anti-idiotypic network [52—56].
The discovery of idiotopes and what the immune system does
with these idiotopes are recent observations with important
implications for the regulatory process. Idiotopes are unique
protein determinants which appear within the T cell receptor
and in or near the antigen-binding variable region of the
antibody molecule. An idiotype identifies the total collection of
all idiotopes expressed by these immune products (Fig. 3).
Idiotypic determinants are encoded by variable region genes
[56, 57], and B or T lymphocyte subpopulations responding to a
particular molecular region of an antigen will share similar
idiotypic determinants. These idiotypes are called individual
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Fig. 2. The murine immune response to a conventional antigen characterized in three stages. All immune responses have an induction process, an
immunoregulatory phase, and an effector response. During the induction process most complex antigens are presented to a helper T cell through an
antigen-presenting cell such as a macrophage or dendritic cell. The helper T cell responds in a fashion restricted by the major histocompatability
complex. These activated helper T cells have three general functions. First, they formulate the effector response by stimulating B cells to mature
into antibody secreting plasma cells, precursor killer cells to differentiate into cytotoxic T cells, and precursor delayed-hypersensitivity cells to
mediate a cell-mediated effector response; second, the activated helper T cell induces a regulatory response to limit its own effect. This feedback
suppression is induced by stimulating an intermediate T cell to differentiate into a suppressor cell, and; third, helper cells can sometimes induce the
intermediate T cell to differentiate into other helper I cells. The control signals which modulate the differentiation of the intermediate T cell are
poorly understood. While further T cell help or suppression may be more important at one time or another, feedback suppression must eventually
evolve for the general economy of the host.
idiotypes because they are shared by a very limited number of
immune cells [56, 58]. Consequently, they also serve to distin-
guish between the many different clones of T and B lympho-
cytes participating in the overall immune response. Because an
individual idiotype is so unique, it is unlikely to have ever been
seen by the immune system prior to antigen-recognition. When
clones of antigen-reactive cells start to expand, these idiotypes
are processed by the immune system as new antigens. That
idiotypes can be immunogenic means that T cell receptors and
antibody molecules not only bind antigens but can become new
antigens themselves, There is, of course, a second kind of
idiotype called a common or cross-reactive idiotype [54, 56]. In
some immune responses this cross-reactive idiotype is shared
by many different groups of clones responding to an antigen. In
this case each of the clones in the group expresses an individual
idiotype, but also share common idiotypes. Cross-reactive
idiotypes are different than individual idiotypes because cross-
reactive idiotypes can be recognized by the immune system
prior to the introduction of antigen. This occasionally occurs
because common idiotypes are more represented among poten-
tial antigen-reactive clones than any individual idiotype. Fur-
thermore, such cross-reactive idiotypes may be ideal regulatory
molecules as one anti-idiotypic repertoire could control the
activity of many clones [54].
The immune response made to idiotypic determinants is
referred to as anti-idiotypic and results in the production of anti-
idiotypic antibodies and idiotype-reactive cells [56]. Because
idiotypes are encoded by variable region genes, they can also
share the molecular structure of the antigen-combining site of
the primary antibody or T cell receptor. One by-product of this
molecular relationship is that some anti-idiotypic immune prod-
ucts will resemble or represent an "internal image" of the
inciting antigen [52, 59, 60—62]. In Figure 3 this is visually
symbolized by comparing the box-like structures representing
both the antigen and the anti-idiotypic immune products. It
should be pointed out, however, that only some of the anti-
idiotypic immune products might be expected to resemble the
antigen [59]. Nevertheless, such observations leave one with
the provocative thought that the anti-idiotypic repertoire of
each individual might already contain molecular representa-
tions of most conventional antigens we are likely to encounter
in our environment [52, 59, 60]. The implications of these
considerations are several: (1) It would seem that most conven-
tional antigens are not really so foreign; (2) because anti-
idiotypic antibodies may be recognized as antigen, it is possible
that regulatory processes already exist prior to external antigen-
ic challenge; (3) exposure to an external antigen may only upset
this dynamic regulatory process with the net result depending
on the responding composition of opposing forces, and; (4) in
disorders of immune regulation, antibodies mimicking self-
antigens may be able to initiate immunologic injury. The control
mechanisms and signals which operate this integrated network
are largely undefined. Whether cross-reactive idiotypes are
functionally more important to the regulatory process than
individual idiotypes is still unclear [59, 60].
The actual development of an anti-idiotypic immune response
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Fig. 3.A complex anti-idiotypic immune response. The inset shows a stylized version of an antibody molecule and a T cell receptor. The idiotype
is a unique protein determinant usually found in the antigen-binding variable regions of the antibody or T cell receptor. In this figure the idiotype is
represented by the black dot (•). When a conventional antigen (U) activates an immune response, the expanding clones of antigen-reactive
idiotype-positive cells are eventually recognized by other cells in the immune system as part of an anti-idiotypic immune response (a). The
induction of this anti-idiotypic immune response is initiated by an idiotype-reactive helper T cell which leads to the production of anti-idiotypic
antibodies and idiotype-reactive suppressor T cells. Both the antigen-reactive and idiotype-reactive suppressor T cells eventually limit the
expansion of the antigen-reactive immune response. These suppressor cells are modulated by anti-idiotypic antibodies and idiotypically-defined
suppressor factors. Although anti-idiotypic antibodies can bind idiotype found on antibodies, its major modulatory effect is probably through the
cell-mediated network. The final suppressive signal (thick black lines) has not been formally established but is probably cell-mediated. The
suppressive signals produced by antigen and idiotype recognition tend to down-regulate this complex response to antigen and, thus, serve the
general economy of the host.
is as complex as the immune response to the original antigen.
This second-order immune response is often marked by the
appearance of anti-idiotypic antibodies [56]. Antibodies ex-
pressing idiotype can exist in the circulation as complexes with
anti-idiotypic antibodies [63], and even as renal immune depos-
its [14]. Anti-idiotypic immunity can be immunoenhancing [64,
65] but is generally suppressive [54, 64—66] such that the
immunologic function of the lymphocytes expressing the idio-
type usually declines with the appearance of anti-idiotypic
regulation [56]. The actual mechanism, however, for down-
regulating the activity of lymphocytes expressing certain idio-
types is not necessarily by the direct neutralizing effects of anti-
idiotypic antibodies [67]. The mechanism of anti-idiotypic sup-
pression, in many cases, appears to be mediated by a complex
interplay between antigen-reactive and idiotype-reactive sup-
pressor T cells (Fig. 3). These suppressor T cells are modulated
by idiotypically-defined suppressor factors as well as by anti-
idiotypic antibodies [56, 64, 66]. The final suppressive signal
that inhibits the antigen-reactive immune response is still unre-
solved. In some experimental systems it may be mediated by a
suppressor T cell effect [66]. These suppressor systems collec-
tively operate as if they were closely interrelated, coordinated,
and precise enough to tightly control expanding clones of
antigen-reactive lymphocytes.
Thus, the effectiveness of the regulatory response depends on
the accurate recognition of complementary cell-surface recep-
tors. The coordination of this network is generally quite good so
that under normal circumstances perturbations of the immune
system by antigen can be controlled internally to efficiently
diminish the development, relative availability, or chronic
expression of detrimental mediators of immunopathology.
Altered regulation in experimental models of immune-
mediated renal disease
Most of what is known about the role of regulatory systems in
immune-mediated renal disease comes from the study of experi-
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Fig. 4. Suppressor cell feedback defects in auloimmune mice at several
different points within the feedback circuir[12J. NZB mice fail to induce
suppressor T cells (Ly 2,3), helper T cells (Ly l) from MRL/l mice do
not seem to respond to engendered suppressor cells (Ly 2,3), and
BxSB mice cannot induce feedback suppression from the intermedi-
ate/amplifier cells (Ly I ,2,3). Thesedefects in suppressor cell genera-
tion may further limit the regulatory response of these autoimmune
mice.
mental animals. These observations form the basis for looking
at immunoregulatory function in humans, a subject which will
be discussed later. Because this area of research is so new it is
natural to expect that much of the information will be incom-
plete. The examples used in this text are cited to illustrate
selected points about the regulatory process in experimental
glomerulonephritis, interstitial nephritis, and transplant
enhancement.
Before each of these renal problems is discussed separately,
it would be useful to consider a frame of reference from which
the principles of immune regulation can be applied to the
development of renal injury. The regulatory process can theo-
retically influence the development of immune-mediated renal
disease in two general ways. First, an expected regulatory
response to a nephritogenic antigen could be delayed or fail to
appear [20, 23]. In this instance the immune response cannot be
terminated and, under such circumstances, a progressively
destructive lesion would be expected. Second, a component
cell or mechanism in the normal regulatory process could cease
to operate or fail to develop such that any number of autoreac-
tive immune responses would spontaneously arise to produce
mediators of renal injury [12, 15, 18, 19, 21, 24]. A rather
straight-forward illustration of the latter situation can be dem-
onstrated in mice experimentally depleted of T cells (Table 1).
Mice that only have B cells and monocytes cannot make T cell-
dependent immune responses, nor do they usually demonstrate
any obvious pathology commonly equated with autoimmune
disease [12]. If these B cell mice are reconstituted with T helper
cells (Ly 1 + cells), a variety of autoantibodies are then pro-
duced, and their kidneys accumulate immune deposits produc-
Table 1. Immunologic defects in reconstituted micea
Nephritogenic
Selectively reconstituted mice
Presence of
autoanti-
bodies"
immune deposits
producing
glomerulonephritis
B cells alone —
B cells and helper T cells (Ly 1) +++ ++÷
B cells, helper T cells (Ly 1) and
suppressor T cells (Ly 2,3k)
Modified from Cantor and Gershon [121.
b The antibodies include antithymocyte, antierythrocyte, and antithy-
roglobulin antibodies.
ing glomerulonephritis. Further, repopulation with suppressor
T cells (Ly 2,3k cells) can partially ameliorate the autoimmune
condition as well as reduce host morbidity. This model of I cell
reconstitution is somewhat analogous to what has been ob-
served previously in nude athymic mice. The nude mouse has a
rudimentary thymic anlage, a marked impairment of T cell
function, and a partial deficiency of selected immunoglobulins
[68—71]. T cell differentiation can occur after treatment with
thymic hormones or following viral infections suggesting that
prothymocytes are present in the affected mice [72]. While it is
generally agreed that T cell function is severely impaired, there
are low levels of T helper cells present in some strains [73]. 1
suppressor cells, however, have not been observed [74]. Under
the conditions of potential T cell help, and in the native
environment of the laboratory mouse, autoantibodies can ap-
pear and immune complex renal disease has been observed [75].
Such immune complex disease is less likely to occur when the
mice are kept in germ-free living conditions [75, 76]. In this
protected environment the lack of exposure to bacterial-derived
B cell activators and the absence of viral infections seems to
diminish any underlying tendency toward autoimmunity. It
should be noted that a normal host confronted with new
environmental antigens can usually handle them without delete-
rious effect. This is not always the case with viruses. Viruses
can enter the genetic machinery of the cell and are capable of
altering the immune system, sometimes producing chronic
immune complex disease in glomeruli [77]. One particular
model of infection that has been investigated extensively is that
of lymphocytic choriomeningitis virus in young mice [20]. Viral
innoculation during the neonatal period produces a carrier state
associated with focal hepatitis, generalized lymphoprolifera-
tion, immune complex glomerulonephritis, and uremia [77]. The
virus-infected cells of these animals may alter major histocom-
patability antigens which presumably stimulate the immune
system on the basis of a reaction to modified self [51]. When T
lymphocytes from adult mice sensitized to the virus are adop-
tively transferred into the carrier animals, the systemic illness
in the recipients is largely abrogated and the renal disease
improves [20]. This latter experiment suggests that effective
regulatory function may be age-dependent. In this case the
adult mouse could provide an appropriate suppressor T cell not
generated at a younger age. All three of these experimental
models also emphasize the important requirement that all T cell
subsets need to be present for a balanced control of the immune
system. Furthermore, the presence or absence of a regulatory
NZB
B x SB —* — MRL!l
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system may easily affect the definition of chronicity during the
natural history of an autoimmune disease.
A more thorough analysis of immunoregulatory function has
been performed in autoimmune mice with immune deposit
glomerulonephritis [12, 16—18,781. These groups of mice (NZB,
NZB/W, MRL/l, and BxSB) represent useful experimental
models for examining the influence of altered regulatory sys-
tems on the production of mediators of renal injury. Each of
these different strains of mice have a variety of genetic defects
[16, 18, 79]. Some of these defects are unique to a particular
strain and suggest that the immunologic basis for immune
complex disease may be very heterogenous [18]. In all of these
mice a number of immunologic aberrations in T and B cell
functions have been associated with the development of immu-
nopathology [13, 16, 18]. Several of these strains exhibit a
hyperactivity of B cell function [80, 81] as well as produce a
wide array of autoantibodies to polynucleotides, phospholipids,
and other compounds. Some of these antibodies have a com-
mon specificity for sugar-phosphate ligands which comprise
portions of many of these self-antigens [17, 82]. This latter
observation suggests that the apparent heterogeneity of auto-
antibodies produced by these mice is not nearly as great as was
once assumed. Defects in the regulation of T cell function have
also been observed which may further aggravate B cell hyperac-
tivity [12, 18, 83, 84]. Recent experiments indicate that NZB
mice have a malfunction in the intermediate T cell (Ly, l,2,3)
which provides suppressor cells responsible for feedback sup-
pression (Fig. 4) [12]. MRL/l autoimmune mice have a circuit
defect in a completely different site in the feedback system. In
these mice the helper cell (Ly l) is capable of inducing
antibody production and feedback suppression but is unable to
respond to the suppressor signal. Preliminary evidence in the
BxSB mouse indicates even a different regulatory defect than
in the MRL/l and NZB strains of mice. Here it appears that I
helper cells fail to induce the intermediate cell to provide
inhibitory activity. While some studies have not always found a
T suppressor cell defect in autoimmune mice [85—881, several
other investigations have reported that such deficiencies may
ultimately contribute to potential failures in T cell modulation
[12, 13, 18, 35, 89—92]. Furthermore, most of the evidence in
support of a suppressor cell defect has only been obtained
during the primary immune response, and the abnormality
seems more related to nonspecific T cell functions [16]. In NZB
mice this suppressor T cell defect can be attenuated by passive-
ly transferring into nephritic mice a lymphocyte-derived sup-
pressor factor [93]. Treatment with this factor significantly
prolongs survival and markedly diminishes the autoimmune
disease. T cells of older MRL/1 mice also seem to exert an
excessive helper cell activity [12]. This finding is consistent
with the observation that disease in MRL/l mice improves with
thymectomy [94, 95] and suggests that alterations in both
suppressor and helper I cells may operationally increase B cell
function in this strain. NZB/W mice, however, worsen follow-
ing thymectomy [94]. Presumably this is because their suppres-
sor T cell defect, aggravated by thymectomy, can no longer
control a hyperactive B cell repertoire. All of this information
collectively implies that a variety of different mechanisms
underlie the regulatory disturbances found in these mice [18].
None of the above findings, however, clearly illuminates a
fundamental basis for the autoimmune response. From a genet-
ic view no one gene can yet account for all immunologic defects
seen during the course of disease [16, 18, 79]. Several recent
studies nevertheless provide some molecular clues which may
further influence our understanding of autoreactivity. Genetic
studies in NZB mice now suggest that autoantibody production
does not necessarily depend on B cell hyperactivity [96, 97, 99,
100]. If this is true then an alternative explanation for autoanti-
body production is required. One possible explanation may be
derived from studies examining anti-idiotypic immunity in these
autoimmune mice. For example, it now appears that NZB mice
cannot make an anti-idiotypic immune response to certain
antigens [98] including some autoantibodies [15]. If, however,
NZB mice are hybridized to other normal strains, the F1
hybrids spontaneously produce an anti-idiotypic immune re-
sponse which suppresses the production of some autoantibod-
ies [15]. These findings collectively implicate a regulatory
abnormality in autoimmune mice which, under normal circum-
stances, would control autoreactive lymphocyte clones ex-
pressing certain variable region gene products (Fig. 5). To look
at this situation more closely, clonal analysis of the anti-DNA
antibody repertoire has been performed in NZB/W mice using
hybridoma technology [99]. In this study 12 different clonotypes
of anti-DNA antibodies were recognized in 13 clones generated
from a fusion of a single mouse spleen. This places the total
anti-DNA clonal repertoire in the NZB/W mouse at 80 different
clonotypes when projection analysis is used, While 12 of the 13
clones were different in some way, eight of the 13 clones shared
a common idiotype indicating that some parts of the variable
regions of these antibodies were conserved and related. A
common or cross-reactive idiotype was also observed among
monoclonal anti-DNA antibodies derived from MRL/l mice
[101]. Finding a common idiotype among autoantibodies sug-
gests that parts of the variable regions of these antibodies are
defined by germ-line genes [17, 101]. Furthermore, the defec-
tive regulation of autoantibody expression in these mice may be
the result of a failure to provide an appropriate anti-idiotypic
repertoire for the down-regulation of these germ-line gene
products [19].
Although a particular anti-idiotypic repertoire may not devel-
op naturally, this does not imply that it or a similar repertoire
cannot be induced by another means. In this regard a recent
study was performed in autoimmune mice to determine if a
relatedness among idiotypes could be used to regulate the
expression of autoantibodies [102]. A monoclonal antibody to
double-stranded DNA expressing a high-frequency idiotype
was repetitively injected into cohorts of NZB/W mice. Serial
measurements indicated that mice treated in this fashion had
significantly delayed death from nephritis and lower titers of
antibodies to double-stranded DNA. These injections of a
monoclonal antibody were shown by isoelectric focusing to
elicit anti-idiotypic antibodies against the injected anti-DNA
antibody. It would be of further interest, of course, to know if
this anti-idiotypic immunity could be transferred to untreated
mice with suppressor T cells. The anti-idiotypic immune re-
sponse induced in treated mice more than likely involves a
process more complex than the simple induction of anti-
idiotypic antibodies. Other mechanisms of disease suppression
might also be equally involved. In conclusion, autoimmune
mice seem to have multiple defects in their immunoregulatory
systems. These defects become more obvious with age and
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Fig. 5. Overview of the immune response
produced by autoimmune mice (NZBIW,
MRLI, and BxSB). These mice exhibit a
variety of genetic defects which underly a
wide spectrum of immunoregulatory
disturbances. No one genetic defect, however,
totally explains the natural history of their
immune complex disease. The immune
repertoire in these mice is altered such that
autoantibodies appear in association with, but
not necessarily related to, the hyperactive
function observed among B cells producing
immunoglobulin. These mice also have a
variety of suppressor T cell defects which
probably contribute to the overall regulatory
disturbance. In some strains of autoimmune
mice there is a recognized defect in anti-
idiotypic regulation which could be predicted
or suspected from the failure to generate
primary suppressor cell signals. As B cells
producing autoantibodies may share a
common idiotype (at least in the case of anti-
DNA antibody secretion), one hypothesis to
explain the production of autoantibodies may
be the failure to produce a regulatory anti-
idiotypic immune response against these
common idiotypes. The result of such a
failure, in the presence of other genetic
disturbances, might be the generation of
immune complex disease. More data is needed
to clarify this supposition.
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Fig. 6. Immunization of rodents with tubular
basement membranes (TBM) induces the
development of anti-tubular basement
membrane disease. The immune response
producing the interstitial nephritis includes the
generation of anti-TBM antibodies and a cell-
mediated reaction in the kidneys probably
involving antigen-reactive T cells.
Concomitant with the appearance of these
mediators of interstitial injury is the
development of polyclonal T cell suppression.
This nonspecific suppressive effect may
influence the further generation of associated
immune responses. One of these associated
responses is the development of anti-idiotypic
immunity. As a hypothesis, this polyclonal
suppression may limit the host's ability to
regulate the anti-TBM response, and as a
result, leave the disease process in an
operationally active mode.
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involve both the T cell repertoire and the anti-idiotypic immune
response. Since both processes are interrelated during the
normal course of immune regulation, it would be of great
interest to determine in what way this relationship fails. Such
studies may provide needed information for future attempts to
selectively re-establish control by means of specific immuno-
logic interventions.
In a different renal lesion recent experiments have also begun
to focus on the relationship between T cell function and the
anti-idiotypic immune response. Rodents immunized with renal
tubular basement membrane antigens develop an experimental
interstitial nephritis characterized by the presence of anti-
tubular basement membrane antibodies and the appearance of
an intense mononuclear cell infiltrate [2, 103—106]. In several
recent studies attempts have been made to alter the natural
history of this disease by the induction of anti-idiotypic immuni-
ty. In one experiment guinea pigs pretreated with anti-idiotypic
antibodies against tubular basement membrane antibodies in-
curred a substantial reduction in the development of disease
after immunization [1071. In slightly different studies normal
rats pretreated with tubular antigen-reactive T lymphoblasts
expressing relevant idiotypes also exhibited reduced amounts
of antitubular basement membrane antibodies, markedly re-
duced cellular infiltrates, and evidence of anti-idiotypic immu-
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Fig. 7. Rejection of a mismatched organ allograft through an alloreac-
tive immune response. If the recipient is pretreated with a variety of
protocols designed to reduce the alloreactive response then graft
enhancement can occur. Although there may be other mechanisms of
enhancement, one mechanism that seems effective is the induction of an
anti-idiotypic immune response. The development of anti-idiotypic
immunity can directly limit the function of alloreactive lymphocytes.
The induction of such a process can be achieved by pretreatment
immunizations with alloreactive lymphocytes and antidonor antibodies,
the injection of alloreactive T lymphoblasts, and by the use of blood
transfusions. The mechanism of this anti-idiotypic immunity is com-
plex. It probably involves the interaction of anti-idiotypic antibodies,
antigen-reactive suppressor cells, and idiotype-reactive suppressor
cells. Collectively, these immune responses can inhibit the alloreactive
lymphocytes in the recipient such that a significant rejection of the graft
becomes less likely.
nity [108]. An anti-idiotypic immune response was implicated
by the fact that rats protected from disease developed anti-
idiotypic antibodies which reacted to the antigen-binding region
of a monoclonal antitubular basement membrane antibody.
Anti-idiotypic suppression in this particular experiment seemed
to act by inhibiting the recognition of tubular antigen by
antigen-reactive T cells, and by reducing antigen-receptor affin-
ity among antigen-reactive lymphocytes.
While it is possible to induce anti-idiotypic immunity in this
experimental model of interstitial nephritis, it would also be
interesting to know if such a regulatory immune response
normally develops during the course of disease. From recent
experiments, however, there is little evidence that this, in fact,
does occur [23]. Sera periodically obtained from nephritic
animals over the course of 100 days failed to demonstrate the
presence of anti-idiotypic antibodies when compared with sera
containing anti-idiotypic antibodies against polyclonal idio-
types, or with sera from animals immunized with a relevant
monoclonal anti-tubular basement membrane antibody. It is
possible that part of this apparent failure to develop anti-
idiotypic immunity during the course of experimental interstitial
nephritis may be related to the concomitant development of
polyclonal T cell suppression [23, 109, 110]. Since the recogni-
tion of idiotypic determinants and the production of anti-
idiotypic immunity is a T cell-dependent event [Ill], polyclonal
T cell suppression in a nephritic animal might make an anti-
idiotypic immune response unlikely (Fig. 6). To look at this
more closely, normal rats were immunized with monoclonal
antitubular basement membrane antibody-coated spleen cells
and then challenged 5 days later with the same antibody to
produce a delayed hypersensitivity response in the footpad [23].
When rats also receive T cells from nephritic animals at the time
of immunization with the antibody-coated spleen cells, the
delayed hypersensitivity response was abrogated. T cells from
nephritic animals also blocked a similar delayed hypersensitivi-
ty response to other irrelevant antigens, suggesting that the
development of anti-idiotypic immunity could be thwarted by
polyclonal suppression. These findings raise the important
question of whether anti-idiotypic immunity and its protective
effect can be induced after the disease is present. This question
has been partially answered in NZB mice [102] but remains an
open issue in autoimmune conditions characterized by the
development of polyclonal suppression.
Finally, the subject of idiotype regulation has received re-
newed interest in the area of renal transplantation. The still
elusive goal of organ allografting is to develop an effective
mechanism to induce specific unresponsiveness in the recipient
for donor alloantigens. The induction of specific unresponsive-
ness, in theory, would still leave the immune system capable of
protecting the host from infection and tumors by obviating the
need for nonspecific immunosuppressive drugs. Such unre-
sponsiveness to donor alloantigens would also attenuate the
nephritogenic immune response leading to allograft rejection
[1 12—1 14]. There is probably more than one means for inducing
the immunologic enhancement (tolerance) of renal allografts
[115, 116]. One potential mechanism of unresponsiveness
would be for the recipient to develop an anti-idiotypic immunity
to idiotypes expressed by its own alloreactive clones (Fig. 7).
Such a hypothesis was examined in rats pretreated with anti-
donor serum [117]. Although cellular infiltrates appeared in the
transplants of these pretreated recipients, the severe vasculitis
associated with rejection was not observed; grafts in enhanced
recipients survived for extended periods of time. The state of
enhancement was characterized by low levels of cytotoxic
reactivity among splenic lymphocytes and by the appearance of
serum-blocking factors thought, perhaps, to beimmune com-
plexes or anti-idiotypic antibodies. These studies were extend-
ed in a slightly different protocol where rats were pretreated
both with donor lymphocytes and antidonor serum [118]. Ten
days after this treatment anti-idiotypic antibodies were detected
in the serum of the recipients. If renal allografting was per-
formed at this time, enhancement occurred and rejection was
avoided for the duration of the study period. Furthermore, no
antidonor reactivity was observed in the spleens of these
recipients and, of additional interest, enhancement persisted
despite the gradual fall in anti-idiotypic antibody titers. Using a
similar enhancement protocol, it was also observed that adop-
tively transferred thymocytes harvested from enhanced and
organ-engrafted donors could significantly prolong the survival
of other grafts in syngeneic recipients [119]. The enhancing
effect was limited to transplants among MHC haplotypes used
in the original enhancement protocol, and the transferred
suppressor cells have not as yet been identified as either
antigen-reactive or idiotype-reactive. If rats are pretreated with
donor lymphocytes and monoclonal antibodies to class I or II
MHC antigens, partial enhancement can also be achieved [120].
If the enhancing antibodies are anti-idiotypic for monoclonal
antibodies against class I antigens, a similar effect can be seen.
Neither the monoclonal antibodies nor the preformed anti-
idiotypic antibodies achieved quite as good an enhancing effect
as conventional antidonor serum. These latter findings suggest
that anti-idiotypic antibodies and monoclonal antibodies may
not be completely enhancing if the molecular regions they see
are only shared by a single or limited number of alloreactive
clones. In a further set of experiments rats pretreated with
alloantigen-reactive T lymphoblasts in adjuvant developed anti-
idiotypic antibodies, reduced lymphocyte reactivity in mixed
lymphocyte culture, suppressor T and B cells, cytotoxic T cells
for clones reactive to donor antigens, and the ability to carry
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skin and organ allografts for extended periods [121—126]. These
important and well characterized studies clearly implicate a
very complex interplay between the humoral and cell-mediated
immune response during the development of anti-idiotypic
immunity leading to specific unresponsiveness to donor alloan-
tigens. No one part of the immune system may totally provide
the complete suppressive effect.
Immune regulation in human renal disease
Experimental studies in animals provide a strong basis for
believing that regulatory disturbances may influence the natural
history of immune-mediated renal disease in humans. This
conclusion is tentative, however, as there are few renal diseases
in which the regulatory process has been examined beyond
initial cursory observations [8]. The problem of doing this kind
of research in humans is compounded by the genetic diversity
within the species, the recognition of disease in groups of
patients at different stages of development, and a tendency to
superimpose only one immunologic mechanism onto a particu-
lar pathologic lesion that may be more heterogenous than we
presently believe. Despite these qualifications, there is some
evidence implicating a role for the immunoregulatory process
during the development of renal injury in humans.
Perhaps the earliest observation that altered T cell function
may be associated with human glomerulonephritis came from
the study of a patient with hereditary thymic dysplasia [241.
This individual had hypoplastic lymphoid organs, no germinal
centers, a decreased capacity to respond to extrinsic antigens,
and an abnormality in the distribution of immunoglobulins.
These findings are reminiscent of the defects previously ob-
served in nude mice [127]. The mechanism for the development
of glomerulonephritis in this patient would be hypothetically
based on a presumed failure in the modulating influence of the T
cell repertoire, More than 10 years passed before another study
appeared suggesting that patients with nil lesion may have an
abnormality in T cell regulation [128]. In a subsequent investi-
gation a lymphokine was found which could alter glomerular
permeability to serum proteins [129]. It was postulated that the
lymphokine was secreted because of an imbalance in thymic
function. Other investigators have also observed a circulating
factor in these patients which can suppress the activation of T
lymphocytes by mitogens [130]. It has since been reported that
patients with nil lesion have increased levels of mitogen-
induced suppressor T cells [131]. Although these studies sug-
gest a role for altered T cell function in the pathogenesis of nil
lesion, they also only describe nonspecific immunologic effects.
In particular, it is unclear as to whether these changes in T cell
function are related to the primary stimulus for disease or to
something else. A mechanism for the polyclonal suppressive
effect was suggested recently by the finding that most patients
with nephrotic range proteinuria, regardless of the pathologic
lesion, had a decrease in mitogen-induced lymphocyte prolif-
eration [132]. Such findings support the idea that a metabolic
defect in nephrotic patients may alter the regulatory function of
the immune system.
With the recognition and identification of T cell subsets in
humans has come the observation that changes in the normal
ratio of T cell subsets in the peripheral blood may characterize
certain human kidney diseases [133]. In particular, patients with
membranous glomerulonephritis, IgA disease, and focal gb-
merular sclerosis seem to have an increase in helper/suppressor
cell ratios above normal. Patients with lupus renal disease seem
to have a low or normal T cell ratio [18]. Other studies,
however, have reported an unpredictable relationship between
helper and suppressor T cells in patients with these glomerular
lesions [133, 134]. One of the most consistently described
defects in T cell subsets nevertheless has been observed in
patients with IgA-IgG nephropathy. Blood samples from some
of these patients demonstrate elevated amounts of circulating
IgA [135—137] and an increase in IgA-secreting B cells [137,
138]. Preliminary evidence reveals that the suppressor cell
subpopulation (OKT8) may be reduced [133], and that in-
creased IgA production may be associated with a deficiency in
IgA-specific suppressor T cells [21]. Given what is known about
immunoregulatory circuits, the absence of the suppressor cell
subpopulation could prevent patients with IgA-IgG nephrop-
athy from effectively modulating their IgA response. This
would leave the disease process in an operationally active
mode. While this hypothesis is appealing, not all of the collect-
ed data is consistent with this view. Not all patients have an
elevated level of circulating IgA, nor an IgA-specific suppressor
cell defect [139]. A serial study of a cohort of patients will
probably be required to clarify these issues.
For many years systemic lupus erythematosus has also
served as a prototype model for immune complex disease
producing renal injury in humans. Much has been learned about
the role of the systemic immune response in the modulation of
immune deposit formation using the previously described auto-
immune mice as an experimental frame of reference. It is now
clear that human regulatory processes can be as complicated as
any observed in these mice. Patients with systemic lupus
erythematosus have been studied intensively by a number of
immunologic techniques. These individuals produce a variety of
autoantibodies including anti-DNA antibodies which can be
deposited in gbomeruli from the circulation as complexes or,
perhaps, by an in situ mechanism [140, 141]. These patients also
have multiple defects within their immunoregulatory systems
[18, 142]. Hyperactivity of human lupus B cells [143], defective
suppressor T cell function [18, 142], and circulating anti-
suppressor T cell antibodies [144, 145] have all been described.
These findings would suggest the immune system in lupus
cannot control B cell responses producing pathogenic autoanti-
bodies. The data mentioned so far, however, do not point to a
fundamental defect which would predict this wide array of
immunologic disturbances. There is some feeling that the
immunologic aberrations in this disease are so broad that any
attempt to force all the data into a common thread of events
might be inappropriate. Nevertheless, a recent study has shown
what appears to be an inverse relationship between the pres-
ence of anti-idiotypic antibodies to anti-DNA antibodies and the
activity of clinical disease [146]. In this study sera was obtained
from patients with active disease and from those same patients
in remission. Remission sera, depleted of anti-DNA antibodies
and free DNA, were able to inhibit the binding of DNA to
F(ab')2 fragments of anti-DNA antibodies obtained from active
sera. The mechanism for the induction of this anti-idiotypic
immunity was not specified. Inhibition was best observed with
autobogous remission sera rather than with sera from unrelated
inactive patients, suggesting that anti-idiotypic antibodies from
one lupus patient may not be directed to the same array of
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idiotypes expressed by other patients. Of further interest,
however, sera from normal individuals previously exposed to
lupus patients or lupus blood products could cross-react and
inhibit the binding of anti-DNA antibodies from unrelated
patients. These normal individuals who occasionally have ab-
normal serologies [147] may be protected from significant
autoreactivity partially by an anti-idiotypic immunity directed
against many individual idiotypes as a result of exposure to
many different patients or to a common or cross-reactive
idiotype, that is, to an idiotype shared by many clones produc-
ing anti-DNA antibodies. These findings suggest that normal
individuals have a broader anti-idiotypic repertoire than those
lupus patients in remission. This difference may, in part, form
the basis for susceptibility to the complete expression of disease
[19]. A further study of these differences between lupus patients
and normal individuals who work with lupus patients may also
provide some interesting insight into the regulatory control of
autoreactive B cell responses producing immune complex renal
disease.
Finally, the topic of immune regulation has now assumed a
pre-eminent place among mechanisms for suppressing the neph-
ritogenic immune response leading to allograft rejection. While
a variety of drugs has been used to significantly inhibit the
development of rejection [114], it has only recently been
observed that some patients may develop active immunologic
mechanisms producing graft enhancement. For example, sever-
al patients receiving renal allografts have had their immunosup-
pressive drugs virtually stopped for other reasons [148, 149].
Despite this, they still have been able to carry a functioning
transplant for a long period of time. Analysis of their sera has
revealed the presence of an antibody which suppresses the
mixed lymphocyte reaction between responder and stimulator
cells of similar mismatched haplotypes. In proper comparisons
these antibodies bound an idiotype expressed by I cell recep-
tors specific for the mixed lymphocyte reaction, suggesting that
the idiotype was carried by DR antigen-reactive clones in the
recipient. If anti-idiotypic immunity can have an enhancing
effect on renal allografts, it would be useful to have a conve-
nient mechanism for inducing this specific form of unrespon-
siveness to donor alloantigens. Previous experimental work has
shown that rats pretreated with donor alloantigens, anti-donor
antibodies, or alloantigen-reactive T lymphoblasts all develop
an anti-idiotypic immunity leading to transplant enhancement
[116—126]. Such immunization protocols are not as yet really
feasible in humans. One alternative immunization protocol has
been the use of blood transfusions. Rats pretreated with donor-
specific blood have carried grafts for prolonged periods in
selected donor-recipient strain combinations [150]. For the last
few years, it has been observed that patients receiving various
numbers of blood transfusions, probably not just prior but at
some point before renal transplantation, have also had better
allograft survival [151, 152]. These findings seem to apply to
recipients of either living-related or cadaveric transplants. The
whole issue of blood transfusions in transplantation has been
treated recently by several informative reviews [153, 154].
Although there may be several mechanisms of enhancement
[115, 116, 154], it would seem that blood transfusions can often
induce antibodies against a T cell receptor specific for HLA-
D/DR antigens [155]. These antibodies will inhibit only certain
mixed lymphocyte culture combinations and are probably not
directed toward common determinants on the surface of the
recipients' T lymphocytes. Furthermore, patients who maintain
long-term functioning allografts have had these antibodies,
whereas patients rejecting their grafts have not [l56j. The
induction of anti-idiotypic immunity following transfusion may
be marked by the development of anti-idiotypic antibodies, but
the actual mechanism of enhancement may be more complex.
Reports of inducing suppressor cells following transfusion [157]
may, in fact, be just another aspect of the anti-idiotypic
repertoire.
Transfusion-induced anti-idiotypic immunity may have sev-
eral implications for donor-recipient selection. First, potential
transplant recipients receiving unselected blood transfusions
may only see a beneficial effect if the suitability of the donor is
predicated on the presence of anti-idiotypic antibodies which
can inhibit that particular donor-recipient mixed lymphocyte
reaction [156]. This observation may have special importance
when more than one living-related donor is available, or when
one or more recipients of a mismatched cadaveric transplant are
in the process of being selected. Second, donor-specific transfu-
sions may be a useful way to target specific graft enhancement
[152]. Whether such transfusions are necessary in all recipient-
donor combinations remains to be seen [153].
The aforementioned observations present more evidence that
further studies of regulatory function in immune-mediated renal
disease in humans should be pursued with renewed interest.
The technical feasibility of such studies continues to improve,
and on-going experiments in animals create a firmer basis for
enhancing the designs of future human investigations.
Concluding remarks
The nephritogenic immune response can be mechanistically
defined both at the effector level within the kidney and in terms
of alterations in highly organized regulatory circuits. Recog-
nized defects in these antibody and cell-mediated circuits may
permit the mediators of immunopathology to continue damag-
ing the kidney at the local level. The descriptions of regulatory
processes involving T cells and anti-idiotypic immunity are new
and extremely complex. As more information accumulates, it is
very apparent that many regulatory components are more
integrated than separate. The future mold of this area of
research, however, depends heavily on more basic studies in
animal models. An examination of regulatory functions at this
level and, in these terms, can only promise new and potentially
exciting information. Such studies may ultimately demonstrate
how selective modulation of the nephritogenic immune re-
sponse may be used to diminish host morbidity or even provide
effective immunoprophylaxis.
Appendix
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Germ-line genes, highly conserved immunogenetic informa-
tion passed to progeny by germ cells (sperm and egg). Immune
response genes, genes usually found in the major histocompata-
bility complex which determine an individual's ability to immu-
nologically respond to complex antigens, Variable region
genes, genes which code for the protein sequences that deter-
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mine both the structural basis for antigen-binding as well as the
expression of idiotypes. Idiotope, a unique protein determinant
expressed by variable region genes. Interestingly enough, and
for enigmatic reasons, the genes which code for the variable
region idiotopes on antibody molecules do not seem to be the
same genes which code for idiotopes expressed by T cells
showing a similar antigen-binding specificity. Individual idio-
types, a collection of unique protein determinants expressed by
a very limited number of T or B cells with the same antigen-
binding specificity. Cross-reactive idiotypes, a collection of
unique protein determinants expressed by a frequent number of
T or B cells with the same antigen-binding specificity. These
idiotypes may be important regulatory molecules. Clonotype,
identical cell replicates derived from a single ancestor. MHC,
major histocompatability complex; in humans it is designated
HLA, in mice H-2, and in rats RT1. Genes in this complex
provide most of the important transplantation antigens as well
as antigens essential for the generation of immune responses.
Class I MHC antigens, HLA-A,B,C in humans, H-2D, or K in
mice, and RTI .A in rats. These antigens are found on most
somatic cells and serve as recognition determinants for cytotox-
ic killer cells. Class II MHC antigens, HLA-D/DR in humans,
H-21 in mice, and RTI .B in rats. These antigens are principally
found on accessory cells, B cells, and activated T cells. They
are important recognition antigens for the initiation of T:B cell
or T:T cell interactions. Alloantigens, inherited variations of
self-antigens expressed by allelic genes such that some mem-
bers of the same species have the antigen or a form of the
antigen, while others do not. Accessory cells, macrophages,
dendritic cells, and Ia glomerular cells which can present
complex antigens to T cells in the context of class II MHC
antigens.
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